Drug Profile
Stem cell therapeutics - ExCellThera
Alternative Names: ECT 001; ECT 002; ECT 003; ECT 005; ECT-001 cell therapy; ECT-001-CB; ECT-100; UM 171; UM171 + UM092; UM171 + UM390; UM171-Expanded CB; UM171-Expanded Cord Blood TransplantationLatest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator ExCellThera
- Developer California Institute for Regenerative Medicine; ExCellThera; Fred Hutchinson Cancer Research Center; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Gene therapies; Haematopoietic stem cells therapies; Immunotherapies
- Mechanism of Action CD34 antigen stimulants; Stem cell stimulants; Ubiquitin protein ligase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Haematological malignancies
- Phase II Acute myeloid leukaemia; Lymphoid leukaemia; Myelodysplastic syndromes
- Phase I/II Multiple myeloma
- Phase I Sickle cell anaemia
- No development reported Immunological disorders
Most Recent Events
- 02 Jan 2024 Preregistration for Haematological malignancies in European Union (Parenteral)
- 02 Jan 2024 ExCellThera completes a phase II trial in Myelodysplastic syndrome in USA and Netherlands (parenteral) (NCT04103879; EudraCT-2022-002458-26)
- 12 Dec 2023 ExCellThera plans a phase III trial for Acute leukemia and Myelodysplasias in 2024